Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Combined treatment with h… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma

Artikel i vetenskaplig tidskrift
Författare P. Lindner
Magnus Rizell
Jan Mattsson
Kristoffer Hellstrand
Peter Naredi
Publicerad i Anticancer Res
Volym 24
Nummer/häfte 3b
Sidor 1837-42
ISSN 0250-7005 (Print)
Publiceringsår 2004
Publicerad vid Institutionen för de kirurgiska disciplinerna, Avdelningen för kirurgi
Institutionen för laboratoriemedicin, Avdelningen för klinisk virologi
Sidor 1837-42
Språk en
Ämnesord Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects/ therapeutic use, Female, Histamine/administration & dosage/adverse effects/blood/pharmacokinetics, Humans, Immunotherapy/ methods, Interferon Alfa-2b/administration & dosage/adverse effects, Interleukin-2/administration & dosage/adverse effects, Male, Melanoma/blood/secondary/ therapy, Middle Aged
Ämneskategorier Medicin och Hälsovetenskap

Sammanfattning

BACKGROUND: Histamine inhibits phagocyte-derived production of reactive oxygen species and improves the anti-tumour efficiency of interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) in vitro and in tumour-bearing animals. PATIENTS AND METHODS: In a phase-II study, twenty-seven patients with stage IV melanoma received subcutanous injections of histamine dihydrochloride (histamine) 1.0 mg and IL-2 2.4 MIU/m2 twice daily (BID) days 1-5 and 8-12. IFN-alpha 3 MIU once daily was administered throughout a cycle (days 1-28; n=14). Alternatively, bolus doses of IL-2 10 MIU/m2 BID days 1 and 2 and histamine days 1-28 (n=13) were administered. The aim was to study efficiency (survival and tumour response), toxicity and histamine pharmacokinetics. RESULTS: The median survival time was 11.3 (2.5-45) months. One patient achieved a complete response and 3 patients had partial responses. The compounds were safely self-administered with low toxicity. Plasma histamine concentrations significantly increased after an injection of histamine over 10 minutes (3 +/- 1 vs. 63 +/- 27 nmol/l). CONCLUSION: Histamine, IL-2 and IFN-alpha treatment is safe, well-tolerated and tumour responses were observed. The putative efficiency of histamine as an adjunct to cytokine therapy in metastatic melanoma needs to be confirmed in later randomized trials.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?